| Dr Lucas Aaron Anderson, MD | |
|
2003 Kootenai Health Way, Coeur D Alene, ID 83814 | |
| (208) 625-4000 | |
| Not Available |
| Full Name | Dr Lucas Aaron Anderson |
|---|---|
| Gender | Male |
| Speciality | Orthopedic Surgery |
| Experience | 14 Years |
| Location | 2003 Kootenai Health Way, Coeur D Alene, Idaho |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1073603692 | NPI | - | NPPES |
| 1073603692 | Medicaid | NC | |
| NC2396 | Medicaid | SC | |
| 1073603692 | Medicaid | ID |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208600000X | Surgery | M-13257 (Idaho) | Secondary |
| 207X00000X | Orthopaedic Surgery | 5869285-1205 (Utah) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Canyon Home Care | Salt lake city, UT | Home health agency |
| University Of Utah Hospitals And Clinics | Salt lake city, UT | Hospital |
| Eastern Idaho Regional Medical Center | Idaho falls, ID | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| University Of Utah Adult Services | 0941525273 | 1459 |
News Archive
Researchers at Rush University Medical Center are exploring a new therapy using stem cells to treat spinal cord injuries within the first 14 to 30 days of injury. Rush is only the second center in the country currently studying this new approach.
Competing visual demands and high background noise increase the risk for anesthesiologists missing pulse oximeter pitch changes, shows research.
Venaxis, Inc., an in vitro diagnostic company focused on obtaining FDA clearance for and commercializing its CE Marked APPY1™ Test, a rapid, multiple biomarker-based index assay for identifying patients that are at low risk for appendicitis, today announced that it has filed a 510(k) premarket submission for the APPY1 Test. Venaxis has requested concurrent de novo determination and 510(k) clearance from the U.S. Food and Drug Administration.
A team of researchers headed by Professor Roland Stauber of Mainz University's ENT clinic has identified a molecular mechanism used by cancer cells to "defend" themselves against chemotherapeutics in an attempt to ensure their own survival.
Expensive brand-name medications to lower blood pressure are no better at preventing cardiovascular disease than older, generic diuretics, according to new long-term data from a landmark study.Paul Whelton, MB, MD, MSc, reported the results on Aug. 13 at the plenary session of the China Heart Congress and International Heart Forum in Beijing. Whelton is president and CEO of Loyola University Health System and chairman of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heat Attack Trial (ALLHAT), which has examined the comparative value of different blood pressure-lowering medications.
› Verified 6 days ago
| Entity Name | University Of Utah Adult Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1114321981 PECOS PAC ID: 0941525273 Enrollment ID: O20150209001683 |
News Archive
Researchers at Rush University Medical Center are exploring a new therapy using stem cells to treat spinal cord injuries within the first 14 to 30 days of injury. Rush is only the second center in the country currently studying this new approach.
Competing visual demands and high background noise increase the risk for anesthesiologists missing pulse oximeter pitch changes, shows research.
Venaxis, Inc., an in vitro diagnostic company focused on obtaining FDA clearance for and commercializing its CE Marked APPY1™ Test, a rapid, multiple biomarker-based index assay for identifying patients that are at low risk for appendicitis, today announced that it has filed a 510(k) premarket submission for the APPY1 Test. Venaxis has requested concurrent de novo determination and 510(k) clearance from the U.S. Food and Drug Administration.
A team of researchers headed by Professor Roland Stauber of Mainz University's ENT clinic has identified a molecular mechanism used by cancer cells to "defend" themselves against chemotherapeutics in an attempt to ensure their own survival.
Expensive brand-name medications to lower blood pressure are no better at preventing cardiovascular disease than older, generic diuretics, according to new long-term data from a landmark study.Paul Whelton, MB, MD, MSc, reported the results on Aug. 13 at the plenary session of the China Heart Congress and International Heart Forum in Beijing. Whelton is president and CEO of Loyola University Health System and chairman of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heat Attack Trial (ALLHAT), which has examined the comparative value of different blood pressure-lowering medications.
› Verified 6 days ago
| Entity Name | University Of Utah Pediatric Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1487018974 PECOS PAC ID: 0547552473 Enrollment ID: O20160713000371 |
News Archive
Researchers at Rush University Medical Center are exploring a new therapy using stem cells to treat spinal cord injuries within the first 14 to 30 days of injury. Rush is only the second center in the country currently studying this new approach.
Competing visual demands and high background noise increase the risk for anesthesiologists missing pulse oximeter pitch changes, shows research.
Venaxis, Inc., an in vitro diagnostic company focused on obtaining FDA clearance for and commercializing its CE Marked APPY1™ Test, a rapid, multiple biomarker-based index assay for identifying patients that are at low risk for appendicitis, today announced that it has filed a 510(k) premarket submission for the APPY1 Test. Venaxis has requested concurrent de novo determination and 510(k) clearance from the U.S. Food and Drug Administration.
A team of researchers headed by Professor Roland Stauber of Mainz University's ENT clinic has identified a molecular mechanism used by cancer cells to "defend" themselves against chemotherapeutics in an attempt to ensure their own survival.
Expensive brand-name medications to lower blood pressure are no better at preventing cardiovascular disease than older, generic diuretics, according to new long-term data from a landmark study.Paul Whelton, MB, MD, MSc, reported the results on Aug. 13 at the plenary session of the China Heart Congress and International Heart Forum in Beijing. Whelton is president and CEO of Loyola University Health System and chairman of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heat Attack Trial (ALLHAT), which has examined the comparative value of different blood pressure-lowering medications.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Lucas Aaron Anderson, MD 2003 Kootenai Health Way, Coeur D Alene, ID 83814-6051 Ph: (208) 625-4000 | Dr Lucas Aaron Anderson, MD 2003 Kootenai Health Way, Coeur D Alene, ID 83814 Ph: (208) 625-4000 |
News Archive
Researchers at Rush University Medical Center are exploring a new therapy using stem cells to treat spinal cord injuries within the first 14 to 30 days of injury. Rush is only the second center in the country currently studying this new approach.
Competing visual demands and high background noise increase the risk for anesthesiologists missing pulse oximeter pitch changes, shows research.
Venaxis, Inc., an in vitro diagnostic company focused on obtaining FDA clearance for and commercializing its CE Marked APPY1™ Test, a rapid, multiple biomarker-based index assay for identifying patients that are at low risk for appendicitis, today announced that it has filed a 510(k) premarket submission for the APPY1 Test. Venaxis has requested concurrent de novo determination and 510(k) clearance from the U.S. Food and Drug Administration.
A team of researchers headed by Professor Roland Stauber of Mainz University's ENT clinic has identified a molecular mechanism used by cancer cells to "defend" themselves against chemotherapeutics in an attempt to ensure their own survival.
Expensive brand-name medications to lower blood pressure are no better at preventing cardiovascular disease than older, generic diuretics, according to new long-term data from a landmark study.Paul Whelton, MB, MD, MSc, reported the results on Aug. 13 at the plenary session of the China Heart Congress and International Heart Forum in Beijing. Whelton is president and CEO of Loyola University Health System and chairman of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heat Attack Trial (ALLHAT), which has examined the comparative value of different blood pressure-lowering medications.
› Verified 6 days ago
Dr. Scott Andrew Brown, D.O. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 850 W Ironwood Dr Ste 202, Coeur D Alene, ID 83814 Phone: 208-664-2175 Fax: 208-664-1226 | |
Dr. Jeffrey Robert Rees Lyman, MD Orthopedic Surgery Medicare: Not Enrolled in Medicare Practice Location: 1233 N Northwood Center Ct Ste 101, Coeur D Alene, ID 83814 Phone: 208-457-4211 Fax: 208-773-1473 | |
Douglas Patrick Mcinnis, MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 850 W Ironwood Dr, Suite 202, Coeur D Alene, ID 83814 Phone: 208-664-2175 Fax: 208-664-1226 | |
Justin Luke Smith, DO Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 850 W Ironwood Dr Ste 202, Coeur D Alene, ID 83814 Phone: 208-664-2175 Fax: 208-664-1226 | |
Dr. Christopher Bryce Arena, MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 1233 N Northwood Center Ct Ste 101, Coeur D Alene, ID 83814 Phone: 208-457-4211 Fax: 208-773-1473 | |
Dr. Adam James Olscamp, MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 1233 N Northwood Center Ct Ste 101, Coeur D Alene, ID 83814 Phone: 208-457-4211 Fax: 208-773-1473 | |
Spencer D Greendyke, MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 3318 N Grand Mill Ln, Coeur D Alene, ID 83814 Phone: 208-277-1060 Fax: 208-277-1065 |